Data published in European Urology Focus suggest there is room for improvement in the management of nonmetastatic muscle-invasive bladder cancer (MIBC) in the UK.
The study assessed treatment and survival by disease stage and sex for all newly diagnosed cases of nonmetastatic MIBC in England in 2016 (n=2519).
Radically treated patients had lower Charlson Comorbidity Index (CCI) score.
Fewer surgical patients underwent neoadjuvant chemotherapy (NAC) compared with radical radiotherapy patients. Radical cystectomy was performed in 24%, 37% of whom received neoadjuvant chemotherapy (NAC). Radical radiotherapy was performed in 29%, 48% of whom received NAC.
Nonradical treatments were provided to 47%, with corresponding lower overall survival.
One-year survival was 91% with NAC with RC or RT. It was 90% in those receiving NAC with RC, and 91% with NAC and radiotherapy. One-year survival dropped to 83% with RC or radiotherapy without NAC, 82% in those receiving RC without NAC, and 80% in those receiving radiotherapy without NAC.
Significantly lower one-year survival was seen in females with stage II and III MIBC.
The authors say there is a “pressing need to determine the reasons underlying this finding”.
